Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. theeoe

theEoE

A novel drug candidate for the treatment of Eosinophilic Esophagitis - an innovative solution for a significant unmet medical need

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 theEoE project word cloud

Explore the words cloud of the theEoE project. It provides you a very rough idea of what is the project "theEoE" about.

epithelial    candidate    modulating    ip    esophagitis    prioritized    generating    health    efficacy    esophagus    europe2020    treatment    28    fits    line    cellular    modulation    healthier    persists    remodeling    causing    sustainable    inflammatory    allergens    diseases    blood    manufacturing    thanks    points    series    barriers    discovery    first    patients    progression    people    inflammation    time    eosinophils    innovation    investing    benefit    modifies    white    toxicology    regurgitation    bioavailability    occurs    lower    theeoe    nausea    uncontrolled    foods    patented    difficulty    approved    proprietary    fewer    symptoms    clinical    decision    pain    complications    integrity    drug    embryo    payers    technologies    pathologies    promotion    company    offers    therapy    wellbeing    risk    applies    injury    compounds    revolutionary    eosinophilic    tissue    persistent    indications    possibly    reduces    polarity    cells    disease    revenue    spending    swallowing    topical    environmental    perfectly    fly    cell    smarter    necessarily    accumulate    local    elicited    vomiting    platform    physicians    thelitetm    cure    thelial    eoe   

Project "theEoE" data sheet

The following table provides information about the project.

Coordinator		 THELIAL TECHNOLOGIES SA 

Organization address
address: PARQUE TECNOLOGICO DE CANTANHEDE, NUCLEO 4, LOTE 3
city: CANTANHEDE
postcode: 3060197
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Portugal [PT]
 Project website http://www.thelial.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THELIAL TECHNOLOGIES SA PT (CANTANHEDE) coordinator 50˙000.00

Map

 Project objective

Thelial Technologies, S.A. is a revenue generating drug discovery company that applies its unique, proprietary fly embryo-based technology to find new candidate compounds for the treatment of diseases that can be addressed by cell polarity modulation. By modulating cell polarity it is possible to specifically target a series of indications, where reduced integrity of epithelial cellular barriers is a key to pathologies. Using Thelial’s patented discovery platform theLiTETM the company has identified 28 candidate compounds, of which one – theEoE has been prioritized for further development based on toxicology, efficacy, bioavailability, IP and manufacturing decision points. theEoE will be the first approved product for treatment of Eosinophilic Esophagitis (EoE). EoE is an inflammatory disease of the esophagus elicited by foods and possibly environmental allergens. It occurs when a type of white blood cells, eosinophils, accumulate in the esophagus and persists, causing local injury and inflammation. Currently, there are no specific cure for the EoE, causing patients’ reduced wellbeing due to uncontrolled and persistent symptoms (e.g. high difficulty in swallowing, pain, nausea, regurgitation, and vomiting). Thelial offers a targeted topical treatment that reduces the clinical symptoms, modifies disease progression through tissue remodeling, and increases the duration of treatment response. These features will allow physicians, patients and payers to benefit from a revolutionary new treatment with fewer side-effects, and lower risk of health complications thanks to a better management of the disease over time. By promoting a first in line targeted therapy for EoE, Thelial’s innovation project perfectly fits the “Europe2020 challenges – for a healthier EU” 1) spending smarter but not necessarily more in sustainable health systems and 2) investing in people’s health, particularly through health-promotion programmes.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THEEOE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THEEOE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HEADSpAcE (2019)

Translational studies of HEAD and neck cancer in South America and Europe

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More